Zoetis (ZTS) Issues FY18 Earnings Guidance
Zoetis (NYSE:ZTS) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $2.96-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.98. The company issued revenue guidance of $5.675-5.8 billion, compared to the consensus revenue estimate of $5.62 billion.
Shares of Zoetis (NYSE:ZTS) opened at $79.73 on Friday. Zoetis has a twelve month low of $52.00 and a twelve month high of $81.40. The stock has a market cap of $38,850.00, a price-to-earnings ratio of 41.96, a P/E/G ratio of 1.64 and a beta of 1.07. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 21.97% and a return on equity of 64.54%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the prior year, the firm posted $0.47 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. analysts anticipate that Zoetis will post 2.36 EPS for the current fiscal year.
A number of analysts recently issued reports on ZTS shares. Zacks Investment Research downgraded shares of Zoetis from a hold rating to a sell rating and set a $83.00 price target on the stock. in a report on Saturday, January 13th. Morgan Stanley raised shares of Zoetis from an equal weight rating to an overweight rating and set a $80.00 price target on the stock in a report on Wednesday, November 29th. Jefferies Group reissued a buy rating on shares of Zoetis in a report on Friday, November 10th. Craig Hallum reissued a buy rating and set a $85.00 price target (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, BidaskClub raised shares of Zoetis from a hold rating to a buy rating in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $80.00.
WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/02/17/zoetis-zts-issues-fy18-earnings-guidance.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.